Anaplastic Lymphoma Kinase-Positive Lung Cancer with Mucoepidermoid Carcinoma Differentiation: A Case Report
Mucoepidermoid carcinoma (MEC) of the lung is an extremely rare tumor, and a standard chemotherapy has not been established. Furthermore, little work has been conducted on the genetic characteristics of MEC. We herein report the case of a 42-year-old nonsmoking male patient who was referred to our h...
Main Authors: | Toshio Sakatani, Yoshio Masuda, Teppei Morikawa, Kazuhiro Usui |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-09-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/510042 |
Similar Items
-
Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
by: Karachaliou N, et al.
Published: (2019-06-01) -
Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status
by: Kitadai R, et al.
Published: (2018-12-01) -
Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA
by: DiBonaventura MD, et al.
Published: (2017-12-01) -
Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
by: Muhammad Wasi Alam, et al.
Published: (2019-07-01) -
Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report
by: Jun Osugi, et al.
Published: (2016-01-01)